Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 8.54 as of 2026-10-06T12:50:27.500Z.
Consensus retrieved: 2026-10-06T08:48:08.479Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:50:27.500Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ecdf9d37c310be267b96a01785260bae1ad3f9733ddde56f295a97d194fe0e96
Forward PE Ratio (8.54) = Dated Quote Price ($25.37) / Consensus Forward EPS ($2.97)
FORWARD PE RATIO
8.54
SECTOR MEDIAN · HEALTHCARE
19.20
median of 132 covered companies
CURRENT VS SECTOR MEDIAN
-55.53%
vs the sector median at left
Amphastar Pharmaceuticals, Inc.
Market Cap
$1.12B
Forward PE Ratio
8.54
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | $1.12B | 8.54 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.14B | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 5.45 |
| Cronos Group Inc. (CRON)vs › | $1.21B | N/A |
Trailing P/E
15.0
reported TTM EPS
Forward P/E
8.5
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.97 implies +75.7% EPS growth vs the reported trailing $1.69.
At the dated quote price of $25.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.97 | $2.77 – $3.32 | 3 | 8.5x |
| 2027-12-31 | $3.18 | $2.92 – $3.58 | 1 | 8.0x |
| 2028-12-31 | $3.38 | $3.13 – $3.60 | 1 | 7.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
